NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Molecular Analysis for Therapy Choice (MATCH) (EAY131)

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

15-C-0200

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Pregnant Women;
Children

Keywords

Targeted;
Pharmacodynamic;
Personalized Medicine;
Genomic

Recruitment Keyword(s)

None

Condition(s)

Neoplasms

Investigational Drug(s)

Afatenib
Crizotinib

Investigational Device(s)

None

Intervention(s)

Drug: Afatinib
Drug: Osimertinib
Drug: Crizotinib
Drug: Trametinib
Drug: Sunitinib
Drug: Vismodegib
Drug: Dasatinib
Drug: AZD5363
Drug: Binimetinib
Drug: Palbociclib
Drug: Nivolumab
Drug: JNJ-42756493 (Erdafitinib)
Drug: Copanlisib
Drug: AZD1775
Drug: LOXO-101
Drug: VS-6063 (Defactinib)
Drug: Pertuzumab
Drug: MLN0128
Drug: AZD4547
Drug: GSK2636771
Drug: Taselisib
Drug: Ado-trastuzumab emtansine
Drug: Dabrafenib
Drug: BMS-986016
Drug: Trastuzumab

Supporting Site

National Cancer Institute

Background:

Targeted agents have been shown to benefit many types of cancer. Researchers want to test if people with cancer with certain genetic changes benefit from treatment with agents targeting those changes.

Objective:

To test any good and bad effects of study drugs or drug combinations. Each drug targets specific genetic changes found in some cancers.

Eligibility:

People ages 18 or older with cancer that has become worse after treatment or has no treatment.

Design:

Participants will be screened with:

-Medical history

-Physical exam

-Blood and urine tests

-Chest x-rays

-MRI or CT scans: They will lay in a machine that takes images of the body.

-ECG, ECHO, or MUGA: A machine records heart function.

-Eye exam

-Skin exam

-Tumor biopsy

The tumor sample will be tested for gene changes. If it shows certain changes, participants will be assigned to a particular treatment. Different treatments will target different changes.

Participants will have several visits over many months.

Participants will take a study drug by mouth 1 to 4 times daily. Or they will get a drug through a vein every 3 weeks.

Participants will keep a medicine diary.

After they stop drug treatment, participants will have follow-up exams:

-Every 3 months for 2 years

-Every 6 months for the third year

Participants may be asked to join another MATCH study treatment if:

-Their cancer gets worse

-They can no longer tolerate the treatment

--Back to Top--

Eligibility

INCLUSION CRITERIA:

- Adults with histologically documented solid tumors and lymphomas whose disease has progressed following at least one line of standard systemic therapy, or for whom no standard therapy exists

-Tumor amenable to image guided or direct vision biopsy and willingness to undergo a tumor biopsy for molecular profiling.

EXCLUSION CRITERIA:

- For each agent (treatment), patients with tumors for which there is an FDA-approved indication, or with histologies that have been shown not to respond or not to have prolonged PFS, will be ineligible.


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Alice P. Chen, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CLINICAL CENTER BG RM 8D53
10 CENTER DR
BETHESDA MD 20892
(240) 781-3320
chenali@mail.nih.gov

Mary Jane Ong
National Cancer Institute (NCI)
BG 10 RM 8D53
10 CENTER DR
BETHESDA MD 20814
(240) 858-3296
maryjane.ong@nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937

Clinical Trials Number:

NCT02465060

--Back to Top--